Mesa R - Search Results

1

Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.

Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R. Gowin K, et al. Among authors: mesa r. Leuk Res. 2017 Sep;60:31-35. doi: 10.1016/j.leukres.2017.06.005. Epub 2017 Jun 13. Leuk Res. 2017. PMID: 28646676 Clinical Trial.

2

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Steensma DP, et al. Blood. 2002 Mar 15;99(6):2252-4. doi: 10.1182/blood.v99.6.2252. Blood. 2002. PMID: 11877307 Free article. Clinical Trial.

3

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Tefferi A, et al. Blood. 2002 May 15;99(10):3854-6. doi: 10.1182/blood-2001-12-0154. Blood. 2002. PMID: 11986248 Free article. Clinical Trial.

4

The therapy of myelofibrosis: targeting pathogenesis.

Mesa RA. Mesa RA. Int J Hematol. 2002 Aug;76 Suppl 2:296-304. doi: 10.1007/BF03165138. Int J Hematol. 2002. PMID: 12430941 Review.

5

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. Mesa RA, et al. Blood. 2003 Apr 1;101(7):2534-41. doi: 10.1182/blood-2002-09-2928. Epub 2002 Nov 27. Blood. 2003. PMID: 12517815 Free article. Clinical Trial.

6

Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.

Mesa RA. Mesa RA. Curr Hematol Rep. 2003 May;2(3):264-70. Curr Hematol Rep. 2003. PMID: 12901349 Review.

7

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.

Mesa RA, Elliott MA, Schroeder G, Tefferi A. Mesa RA, et al. Mayo Clin Proc. 2004 Jul;79(7):883-9. doi: 10.4065/79.7.883. Mayo Clin Proc. 2004. PMID: 15244384

8

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

Arora B, Mesa R, Tefferi A. Arora B, et al. Among authors: mesa r. Leuk Lymphoma. 2004 Dec;45(12):2373-86. doi: 10.1080/10428190400003267. Leuk Lymphoma. 2004. PMID: 15621750 Review.

9

Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A. Mesa RA, et al. Semin Oncol. 2005 Aug;32(4):403-13. doi: 10.1053/j.seminoncol.2005.04.012. Semin Oncol. 2005. PMID: 16202686 Review.

10

Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.

Tefferi A, Dingli D, Li CY, Mesa RA. Tefferi A, et al. Leuk Res. 2006 Jun;30(6):677-80. doi: 10.1016/j.leukres.2005.10.006. Epub 2005 Nov 8. Leuk Res. 2006. PMID: 16288807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

561 results

Search Page

Filters